Vivos TherapeuticsVVOS -9.05%41 3-Year ROIIC % is 26.49 as of Dec. 2025. GuruFocus rates VVOS with a GF Score™ of 41/100 and a GF Value™ of $1.15 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 800 Medical Devices & Instruments companies, Vivos Therapeutics ranks better than 74.5% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Vivos Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 26.49%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Vivos Therapeutics's 3-Year ROIIC % or its related term are showing as below:
VVOS's 3-Year ROIIC % is ranked better than 74.5% of 800
companies
in the Medical Devices & Instruments industry
Industry Median: 1.785
vs VVOS: 26.49
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Vivos Therapeutics 3-Year ROIIC % Related Terms
Vivos Therapeutics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Vivos Therapeutics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VVOS vs XAIR, TNON, BMRA: 3-Year ROIIC % Comparison
For the Medical Devices subindustry, Vivos Therapeutics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivos Therapeutics 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vivos Therapeutics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Vivos Therapeutics's 3-Year ROIIC % falls into.
Vivos Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -19.894 (Dec. 2025) - -25.031 (Dec. 2022) )
/
( 31.177 (Dec. 2025) - 11.786 (Dec. 2022) )
=
5.137
/
19.391
=
26.49%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Vivos Therapeutics (VVOS) has a 3-Year ROIIC % of 26.49 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Vivos Therapeutics and its competitors. According to the industry distribution chart, Vivos Therapeutics ranks #204 out of 800 companies in the Medical Devices & Instruments industry, placing it in the top 25.5%.
Is Vivos Therapeutics' 3-Year ROIIC % too high?
Vivos Therapeutics' current 3-Year ROIIC % is 26.49. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.79. Vivos Therapeutics' value of 26.49 is 1384% above this industry median. Based on the distribution chart, Vivos Therapeutics ranks #204 out of 800 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Vivos Therapeutics has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vivos Therapeutics' 3-Year ROIIC % compare to XAIR and TNON?
According to the Medical Devices & Instruments industry distribution chart, Vivos Therapeutics ranks #204 out of 800 companies for 3-Year ROIIC %. This puts Vivos Therapeutics in the upper half of its industry. The industry median 3-Year ROIIC % is 1.79. Vivos Therapeutics' value of 26.49 is 1384% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.79, based on 800 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vivos Therapeutics's current 3-Year ROIIC % of 26.49 is 1384% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Vivos Therapeutics and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivos Therapeutics's current 3-Year ROIIC % is 26.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Vivos Therapeutics (VVOS) is currently considered Possible Value Trap. The stock's GF Value™ is $1.15, compared to a current price of $0.45 — trading 60.6% below its estimated fair value. The current 3-Year ROIIC % is 26.49 and 1384% above the Medical Devices & Instruments industry median of 1.79. Vivos Therapeutics' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Vivos Therapeutics (VVOS), the current 3-Year ROIIC % is 26.49 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vivos Therapeutics (VVOS) Overvalued in 2026?
Based on GuruFocus' analysis, Vivos Therapeutics stock appears to be undervalued.
The current stock price of $0.45 is trading 60.6% below its estimated GF Value™ of $1.15.
GuruFocus considers Vivos Therapeutics to be Possible Value Trap.
Key valuation signals for VVOS:
3-Year ROIIC %: 26.49
GF Value™: $1.15 vs. price of $0.45 (60.6% below fair value)
Industry Position: 1384% above the Medical Devices & Instruments median (#204 of 800)
No single metric tells the full story. See the VVOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
41GF Score
Get the complete analysis for VVOS
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VVOS has been successfully added to your 
